• Modern approaches to the treatment of bacterial vaginosis and mixed nonspecific vaginitis

Modern approaches to the treatment of bacterial vaginosis and mixed nonspecific vaginitis

HEALTH OF WOMAN. 2017.8(124):89–95; doi 10.15574/HW.2017.124.89  

Golyanovsky O. V., Mehedko V. V., Budchenko M. A.
National Medical Academy of Postgraduate Education P. L. Shupyk, Kiev

The objective: to evaluate the effectiveness of treatment of women with various dysbiotic vaginal conditions with Limenda.
Materials and methods. 58 women of reproductive age with BV and mixed nonspecific vaginitis participated in the study. The main group included 30 women, whose treatment was carried out with Limenda drug. The control group consisted of 28 women, whose treatment was performed according to the standard scheme using a combination of drugs.
Results. Based on the results of control tests, complete elimination of pathogens occurred in 29 (96.67%) patients of the main group and in 26 (92.86%) patients of the control group. Five days after the treatment, all 30 (100%) women in the main group noted complete disappearance of symptoms on the control visit, and 2 (7.14%) of the control group complained of minor discomfort in the vagina, which required continued treatment.
The conclusion. For the treatment of nonspecific vaginitis and bacterial vaginosis, especially chronic and often recurrent forms, it is better to use combined local remedies. The results of this study reliably testify to the high effectiveness of the combined drug Limenda compared with standard treatment regimens.
Key words: vaginitis, bacterial vaginosis, vaginal biocenosis, conditional resistance, metronidazole, miconazole, Limenda.

REFERENCES

1. Aylamazyan EK, Kulakova VI, Radzinskiy VE, Saveleva GM. 2007. Akusherstvo: Natsionalnoe rukovodstvo. Pod red. EK Aylamazyana, VI Kulakova, VE Radzinskogo, GM Savelevoy. M, GEOTAR-Media:1200.

2. Berlev IV, Bahidze EV, Arhangelskaya PA. Znachenie otsenki narusheniy biotsenoza vlagalischa v aspekte diagnostiki i lecheniya preinvazivnyh neoplaziy sheyki matki: 16–21. Bibliogr.: 19–21.

3. Berlev IV, Bahidze EV, Arhangelskaya PA. 2015. Znachenie otsenki narusheniy biotsenoza vlagalischa v aspekte diagnostiki i lecheniya preinvazivnyih neoplaziy sheyki matki. Zhurnal Akusherstva i Zhenskih bolezney 5:16–21.

4. Vulvovaginityi: skrining i lechenie vulvovaginalnogo kandidoza, trihomoniaza i bakterialnogo vaginoza. Obzor prakticheskih rekomendatsiy Obschestva akusherov i ginekologov Kanadyi 2015. MedichnI aspekti zdorov’ya zhInki. 2016. 1:23–28.

5. Gomberg MA, Plahova K. 2005. Infektsii vlagalischa: vzglyad venerologa Terapiya trihomoniaza i bakterialnogo vaginoza: problemy i puti resheniya. Consilium Medicum. 03:210–214.

6. Dovlethanova ER, Abakarova PR. 2013. Vozmozhnost primeneniya kompleksnyih preparatov v lechenii vulvovaginitov polimikrobnoy etiologii. Zdorove zhenschiny 6(82):101–102.

7. Kagramanova ZhA. 2010. Bakterialnyiy vaginoz. Shkola farmakologa: bakterialnyiy vaginoz. Rossiyskie apteki. 23:32–34.

8. Kulakov VI, Prilepskaya VN, Radzinskiy VE. 2006. Rukovodstvo po ambulatorno-poliklinicheskoy pomoschi v akusherstve i ginekologii. M, GEOTAR-Media:1056.

9. Klinicheskie rekomendatsii po vedeniyu bolnyih bakterialnyim vaginozom. Rossiyskoe obschestvo akusherov-ginekologov, Rossiyskoe obschestvo dermatovenerologov i kosmetologov. 2015.

10. Radzinskiy VE. 2009. Zhenskaya konsultatsiya: Rukovodstvo. Pod red. VE Radzinskogo. 3-e izd., ispr. i dop. M, GEOTAR-Media:472.

11. Radzinskiy VE, Hamoshina MB, Kaygorodova LA i dr. 2011. Korrektsiya narusheniy biotsenoza vlagalischa: marsh na meste ili dvizhenie vpered? Doktor.Ru. 9(68):26–32.

12. Radzinskiy VE. 2009. Rannie sroki beremennosti. Pod red. VE Radzinskogo, AA Orazmuradova. 2-e izd., ispr. i dop. M, Status Praesens:480.

13. Saidova RA. 2001. Bakterialnyiy vaginit ili bakterialnyiy vaginoz? RMZh 19:843.

14. Hamoshina MB i dr. 2009. Narusheniya mikrobiotsenoza urogenitalnogo trakta: grani problemyi, perspektivyi korrektsii i profilaktiki. Voprosyi ginekologii, akusherstva i perinatologii 8;5:69–74.

15. Allsworth JE, Peipert JF. 2007. Prevalence of bacterial vaginosis: 2001-2004 National Health and Nutrition Examination Survey data. Obstet Gynecol 109:114. https://doi.org/10.1097/01.AOG.0000247627.84791.91; PMid:17197596

16. Amsel R, Totten PA, Spiegel CA et al. 1983. Nonspecific vaginitis. Diagnostic criteria and microbial and epidemiologic associations. Am J Med 74:14. https://doi.org/10.1016/0002-9343(83)91112-9

17. Barrington JW, Linton D, O’Leary A, Blackwell A, Brick J et al. 1997. Anaerobic (bacterial) vaginosis and premalignant disease of the cervix.J. Obstet. Gynecol. 17:383–5. https://doi.org/10.1080/01443619750112943; PMid:15511897

18. Beigi RH, Austin MN, Meyn LA et al. 2004. Antimicrobial resistance associated with the treatment of bacterial vaginosis. Am J Obstet Gynecol 191:1124–9. https://doi.org/10.1016/j.ajog.2004.05.033; PMid:15507930

19. Boyle DC, Barton SE, Uthayakumar S, Hay PE, Pollock JW et al. 2003. Is bacterial vaginosis associated with cervical intraepithelial neoplasia? Int.J. Gynecol. Cancer. 13:159–63. https://doi.org/10.1046/j.1525-1438.2003.13007.x

20. Boyle DC, Smith JR. 1999. Infection and cervical intraepithelial neoplasia. Int.J. Gynecol. Cancer. 9:177–86. https://doi.org/10.1046/j.1525-1438.1999.99007.x

21. Bosch J, Lorincz A, Munoz N et al. 2002. The Causal relation between human papillomavirus and cervical cancer.J. Clin. Pathol. 55:244–65. https://doi.org/10.1136/jcp.55.4.244; PMid:11919208 PMCid:PMC1769629

22. Bradshaw CS, Tabrizi SN, Fairley CK et al. 2006. The association of Atopobium vaginae and Gardnerella vaginalis with bacterial vaginosis and recurrence after oral metronidazole therapy. J Infect Dis 194:828–36. https://doi.org/10.1086/506621; PMid:16941351

23. Bradshaw CS, Walker SM, Vodstrcil LA et al. 2014. The influence of behaviors and relationships on the vaginal microbiota of women and their female partners: the WOW Health Study. J Infect Dis 209:1562. https://doi.org/10.1093/infdis/jit664; PMid:24285846

24. British Association for Sexual Health and HIV (BASHH) and the Clinical Effectiveness Group (CEG). Revised national guideline for the management of bacterial vaginosis.

25. Cohen CR, Lingappa JR, Baeten JM et al. 2012. Bacterial vaginosis associated with increased risk of female-to-male HIV-1 transmission: a prospective cohort analysis among African couples. PLoS Med 9:e1001251. https://doi.org/10.1371/journal.pmed.1001251; PMid:22745608 PMCid:PMC3383741

26. Eichholzer M, Gutzwiller F. 1998. Dietary nitrates, nitrites, and N-nitroso compounds and cancer risk: a review of the epidemiologic evidence. Nutr. Rev. 56:95–105. https://doi.org/10.1111/j.1753-4887.1998.tb01721.x; PMid:9584494

27. Ferris MJ, Masztal A, Aldridge KE et al. 2004. Association of Atopobium vaginae, a recently described metronidazole resistant anaerobe, with bacterial vaginosis. BMC Infect Dis 4:5. https://doi.org/10.1186/1471-2334-4-5; PMid:15018635 PMCid:PMC362875

28. Fethers KA, Fairley CK, Hocking JS, Gurrin LC, Bradshaw CS. 2008. Sexual risk factors and bacterial vaginosis: a systematic review and meta-analysis. Clin. Infect. Dis. 47:1426–35. https://doi.org/10.1086/592974; PMid:18947329

29. Fethers KA, Fairley CK, Morton A et al. 2009. Early sexual experiences and risk factors for bacterial vaginosis. J Infect Dis 200:1662. https://doi.org/10.1086/648092; PMid:19863439

30. Frankowski A, Wictorowicz K, Kedria W et al. 1997. Lymphocyte subpopulations in the blood of woman with HPV 16-positive and negative cervical cancer. Eur.J. Gynicol Oncol. 18(5):394–6. PMid:9378160

31. Van Schalkwyk J, Yudin MH. 2015. Vulvovaginitis: Screening for and Management of Trichomoniasis, Vulvovaginal Candidiasis, and Bacterial Vaginosis. J Obstet Gynaecol Can 37(3):266-274. https://doi.org/10.1016/S1701-2163(15)30316-9

32. Klebanoff MA, Nansel TR, Brotman RM et al. 2010. Personal hygienic behaviors and bacterial vaginosis. Sex Transm Dis 37:94. 32. Klebanoff MA, Nansel TR, Brotman RM et al. 2010. Personal hygienic behaviors and bacterial vaginosis. Sex Transm Dis 37:94.
https://doi.org/10.1097/OLQ.0b013e3181bc063c; PMid:19823112 PMCid:PMC2811217

33. Klebanoff MA, Schwebke JR, Zhang J et al. 2004. Vulvovaginal symptoms in women with bacterial vaginosis. Obstet Gynecol 104:267. https://doi.org/10.1097/01.AOG.0000134783.98382.b0; PMid:15291998

34. Ling Z, Kong J, Liu F et al. 2010. Molecular analysis of the diversity of vaginal microbiota associated with bacterial vaginosis. BMC Genomics 11:488. https://doi.org/10.1186/1471-2164-11-488; PMid:20819230 PMCid:PMC2996984

35. Marrazzo JM, Thomas KK, Fiedler TL et al. 2008. Relationship of specific vaginal bacteria and bacterial vaginosis treatment failure in women who have sex with women. Ann Intern Med 149:20–8. https://doi.org/10.7326/0003-4819-149-1-200807010-00006; PMid:18591634 PMCid:PMC2630802

36. McClelland RS, Richardson BA, Hassan WM et al. 2008. Improvement of vaginal health for Kenyan women at risk for acquisition of human immunodeficiency virus type 1: results of a randomized trial. J Infect Dis 197:1361–8. https://doi.org/10.1086/587490; PMid:18444793 PMCid:PMC4122228

37. Meltzer MC, Desmond RA, Schwebke JR. 2008. Association of Mobiluncus curtisii with recurrence of bacterial vaginosis. Sex Transm Dis 35:611–3. https://doi.org/10.1097/OLQ.0b013e318167b105; PMid:18418301 PMCid:PMC3793327

38. Nyirjesy P, McIntosh MJ, Steinmetz JI et al. 2007. The effects of intravaginal clindamycin and metronidazole therapy on vaginal mobiluncus morphotypes in patients with bacterial vaginosis. Sex Transm Dis 34:197–202. https://doi.org/10.1097/01.olq.0000235152.98601.d7; PMid:17179772

39. Pavic N. 1984. Is there a local production of nitrosamines by the vaginal microflora in anaerobic vaginosis/trichomoniasis? Med. Hypotheses. 15:433–6. https://doi.org/10.1097/01.olq.0000235152.98601.d7; PMid:17179772

40. Reichman O, Akins R, Sobel JD. 2009. Boric acid addition to suppressive antimicrobial therapy for recurrent bacterial vaginosis. Sex Transm Dis 36:732–4. https://doi.org/10.1097/OLQ.0b013e3181b08456; PMid:19704395

41. Sexually Transmitted Diseases: Summary of 2015 CDC, Совещательный комитет Центров по контролю и профилактике заболеваний США (Centers for Disease Control and Prevention — CDC).

42. Sobel JD, Ferris D, Schwebke J et al. 2006. Suppressive antibacterial therapy with 0.75% metronidazole vaginal gel to prevent recurrent bacterial vaginosis. Am J Obstet Gynecol 194:1283–9. https://doi.org/10.1016/j.ajog.2005.11.041; PMid:16647911

43. Wolrath H, Forsum U, Larsson PG, Boren H. 2001. Analysis of bacterial vaginosis-related amines in vaginal fluid by gas chromatography and mass spectrometry. J. Clin. Microbiol. 39:4026–31. https://doi.org/10.1128/JCM.39.11.4026-4031.2001; PMid:11682525 PMCid:PMC88482

44. Yen S, Shafer MA, Moncada J et al. 2003. Bacterial vaginosis in sexually experienced and non-sexually experienced young women entering the military. Obstet Gynecol 102:927. https://doi.org/10.1016/S0029-7844(03)00858-5; https://doi.org/10.1097/00006250-200311000-00009; PMid:14672465